NASDAQ: MNMD Archives - BioPharmaJournal

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) Issued Its Shareholders and Investors...

Matt Wade - April 27, 2022 0

Mind Medicine Inc. (NASDAQ: MNMD) Receives approval for IND to Continue...

Matt Wade - January 31, 2022 0

US FDA Places Mind Medicine Inc.’s (NASDAQ: MNMD) IND Supporting Phase...

Kate Hudson - January 3, 2022 0

MindMed (NASDAQ: MNMD) Reports Q3 2021 Financial Results and Commences Recruitment...

Kate Hudson - November 24, 2021 0

MindMed Medicine Inc. (NASDAQ: MNMD) Enters Collaboration With Florian Inc. (NASDAQ:...

Kate Hudson - September 3, 2021 0

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) Acquires HealthMode: Commences Clinical Trial...

Matt Wade - June 2, 2021 0

CymaBay Therapeutics Inc (NASDAQ: CBAY) Announces Promising Seladelpar Data In Treatment...

Gavins Felicity - July 5, 2022 0

CymaBay Therapeutics Inc (NASDAQ: CBAY) has announced the presentation of promising seladelpar findings in primary biliary cholangitis (PBC) patients at The International Liver Congress...

Chimerix Inc (NASDAQ: CMRX) Receives $25.3 Million Procurement Contract For TEMBEXA

July 4, 2022

Regulus Therapeutics Inc (NASDAQ: RGLS) Pleased after FDA Approved its Orphan...

July 1, 2022

Cannabis Stocks Deeply Oversold with Big Growth Ahead (TLRY, SGMD, OGI,...

June 30, 2022

Ocugen Inc (NASDAQ: OCGN) Announces the Successful Publication of Positive Outcomes...

June 30, 2022

Tag: NASDAQ: MNMD

Recent Post